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Abstract
Background: Clinical and laboratory data were collected and analysed from patients with Ebola virus disease (EVD)
in Jui Government Hospital in Freetown, Sierra Leone, where patients with EVD were received and/or treated from
October 1, 2014 to March 21, 2015 during the West Africa EVD outbreak.
Methods: The study admitted 285 patients with confirmed EVD and followed them up till the endpoint (recovery
or death). EVD was confirmed by quantitative RT-PCR assays detecting blood Ebola virus (EBOV).
Results: Among the 285 lab-confirmed EVD cases in Jui Government Hospital, 146 recovered and 139 died, with an
overall survival rate of 51.23 %. Patients under the age of 6 years had a lower survival rate (37.50 %). Most non-survivors
(79.86 %) died within 7 days after admission and the mean hospitalization time for non-survivors was 5.56 ± 6.11 days.
More than half survivors (63.69 %) turned blood EBOV negative within 3 weeks after admission and the mean
hospitalization time for survivors was 20.38 ± 7.58 days. High blood viral load (≥106 copies/ml) was found to be
predictive of the non-survival outcome as indicated by the Receiver Operating Characteristic (ROC) curve analysis.
The probability of patients’ survival was less than 15 % when blood viral load was greater than 106 copies/ml.
Multivariate analyses showed that blood viral load (P = 0.005), confusion (P = 0.010), abdominal pain (P = 0.003),
conjunctivitis (P = 0.035), and vomiting (P = 0.004) were factors independently associated with the outcomes of
EVD patients.
Conclusions: Most death occurred within 1 week after admission, and patients at the age of 6 or younger had a
lower survival rate. Most surviving patients turned blood EBOV negative within 1–4 weeks after admission. Factors
such as high blood viral load, confusion, abdominal pain, vomiting and conjunctivitis were associated with poor
prognosis for EVD patients.
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Background
Ebola virus disease (EVD), previously known as Ebola
haemorrhagic fever, is a rare and deadly disease caused
by infection with one of the Ebola virus strains. A
large-scale outbreak of haemorrhagic fever occurred in
southern Sudan between June and November 1976. It
was transmitted by close personal contact and by use of
contaminated needles and syringes in hospitals/clinics
[1]. This outbreak led to the further recognition of the
disease, which was subsequently named Ebola haemor-
rhagic fever. Since then, outbreaks have occurred spor-
adically in Africa.
A 2014 EVD outbreak was the largest in scale in his-
tory, affecting multiple countries in West Africa. In the
2014 outbreak, the first lab-confirmed EVD patient was
reported in May, 2014 in Guinea and since then the
Zaire Ebola Virus (ZEBOV) has rapidly spread across
Sierra Leone and to other West Africa countries. From
March 2014 to December 27, 2015,there were 28 601 re-
ported EVD infections (including confirmed, probable,
and suspected) and 11 300 reported deaths in West
Africa. A total of 853 confirmed infections and 494
deaths of health care workers were reported in Guinea,
Liberia, and Sierra Leone [2].
As of December 23, 2015, the Sierra Leone National
Ebola Response Center (NERC) reported a cumulative
total of 14 339 confirmed EVD cases with 3 955 deaths
(excluding probable and suspected cases) [3]. Situated
on the Atlantic coast, Freetown is the capital and the lar-
gest city of Sierra Leone, and is densely populated with
over 1 million people. Due to the heavy population,
Freetown and its surrounding western region was the
most affected area in this epidemic. As of December 23,
2015, 5 500 confirmed cases had been reported in this
region, accounting for 38.36 % of the country’s total
EVD reported cases [3].
EVD imposed a significant economic burden on the
West African countries affected. Some studies suggest that
due to EVD deaths, life expectancy may have declined in
Liberia and Sierra Leone to a new low since 2001–2003
[4]. This dramatic healthcare crisis, coupled with human
rights and global security concerns, underscored the ur-
gent need for developing resilient healthcare systems, and
called for the domestic and international aides and invest-
ments in these African countries [5].
The clinicians of the Chinese Medical Team (CMT)
managed EVD patients in an Ebola Holding and Treat-
ment Center in Jui Government Hospital, which is also
known as Sierra Leone-China Friendship Hospital. Being
one of the best hospitals in Freetown, Jui Government
Hospital received 773 suspected EVD patients during
the period of October 1, 2014 and March 21, 2015, of
whom 285 were confirmed infected with the virus. All of
the CMT clinicians were from Beijing 302 Hospital, the
largest specialized hospital in China for infectious dis-
ease treatment. The same hospital had successfully man-
aged and controlled the outbreak of Severe Acute
Respiratory Syndrome (SARS), A/H1N1 influenza, and
some other public health emergencies in China.
In this study, we described the clinical presentations,
clinical courses, and the treatment outcomes of all EVD
patients admitted in Jui Government Hospital for care.
We hope this paper provide further understanding and
insights into pathophysiology, clinical manifestations
and treatment impact of end outcomes of EVD.
Methods
Patients and data collection
A retrospective, observational study was conducted
using data collected from all patients with confirmed
EVD who were admitted to the Holding and Treatment
Center of Jui Government Hospital from October 1,
2014 to March 21, 2015. Diagnosis of EVD was made in
accordance with the criteria set by the World Health
Organization (WHO) in the Standard Operating Proce-
dures (SOP) for Managing EVD.
Because Jui Government Hospital was designated as
an Ebola Holding Center (EHC) on October 1, 2014, but
was not approved as an Ebola Treatment Center (ETC)
until January 1, 2015, 152 confirmed EVD patients re-
ceived at this hospital between October 1, 2014 and
January 1, 2015 were immediately transferred to other
treatment centres once confirmed. After January 1, 2015,
all confirmed patients except pregnant women were
treated in Jui Government Hospital; the confirmed EVD
patients who were pregnant women were transferred to
a designated ETC (P.T.S.1 Ebola Treatment Center). We
carried out follow-up studies and data collections from
all confirmed patients (both the patients treated in Jui
Government Hospital and those transferred to other
hospitals) before we finished our mission in March 2015.
Data collected included observations such as the dur-
ation of hospitalization, the date when blood EBOV
turned negative, and the endpoint (recovery or death).
The determination of recovery was based on the clinical
presentations and the interpretation of laboratory find-
ings. Discharge from hospitalization was considered
when the following criteria were met: 1) three or more
days without fever or any other significant symptom, 2)
significant improvement in clinical presentations, 3) a
relatively good general condition, and 4) a negative PCR
result for blood EBOV on the third day of being asymp-
tomatic. If a patient continued to suffer symptoms or
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their condition was not improving, but it was suspected
to be unrelated to EVD, then two blood EBOV tests
were carried out 48 h apart, with at least one test being
done 3 days or more after the onset of symptoms. If
both test results were negative, patients were discharged
or referred to a normal hospital for further care.
The study protocol adhered to the Declaration of
Helsinki, and the ethical clearance was obtained from
302 Military Hospital Medical Ethics Committee and the
Sierra Leone Ethics and Scientific Review Committee,
respectively. The patients were routinely evaluated for
clinical presentations. Data collected included vital signs
at admission, medical history, time points when blood
EBOV turned negative, durations of hospital stay, and
outcome.
EBOV diagnosis and viral load assays
Within 24 h upon admission, EBOV detection assays
were carried out via quantitative RT-PCR using whole
blood samples. If the patient died quickly and the blood
samples were not collected due to time constraints or
poor venous access after death, EBOV detection was car-
ried out using oral swab samples from corpses. Samples
were collected at 16:00 o’clock every day and results
were generated within 6 h. Samples were obtained using
Jui Government Hospital’s collection and processing
protocols, which was described in the emergency-
response guidelines established by the Sierra Leone
Ministry of Health and Sanitation.
Diagnosis testing for EBOV was performed by China
CDC Mobile Laboratory. Total RNA was extracted from
patient peripheral blood samples or swab samples in
Bio-safety Level 3 (BSL-3) facilities. Ebola viral RNA was
then detected using Detection Kit for Ebola virus sub-
type Zaire RNA (Puruikang Biotech Co. Ltd, with PCR
Fluorescence Probing) according to the manufacturer’s
recommendations [6]. For quantification purposes, the
amplicon concentrations were converted to copies of
EBOV per milliliter (method provided by China CDC
Mobile Laboratory).
Treatment protocol
The care protocols for confirmed Ebola cases before and
after June 1, 2014 were similar and were in accordance
with the SOP of WHO and the Ministry of Health of
Sierra Leone. The treatment protocol was as follows: All
adult patients received 10 mg of vitamin K and 120 mg
of sodium artesunate immediately upon admission. After
24 h all adult patients with confirmed EVD received 2 g
of ceftriaxone every 24 h, 500 mg of metronidazole every
8 h, 500-1 000 ml of Ringer’s lactate every 12 h, and
500-1 000 ml of dextrose saline (5 % and 0.9 %, respect-
ively) every 12 h. All the above medications were admin-
istered intravenously. Adult patients also received a
20 mg zinc sulfate tablet daily, a 400 mg acetaminophen
tablet every 12 h, and 8 mg of ondansetron injection
intravenously as needed for nausea or vomiting. After
the first 3 days, continuing therapy included a 400 mg
metronidazole tablet every 12 h for 7 days, a 500 mg
cefuroxime tablet every 12 h for 5 days, and a 400 mg
acetaminophen tablet every 12 h. The protocol for chil-
dren was similar but the dosage was adjusted according
to their body weight. Oral rehydration solution and juice
were provided on an as needed basis. We transfused
more fluid to the patients with profound GI losses and
those unable to take oral fluids or medications. Cur-
rently, early supportive care, empiric antibiotic therapy,
and maintenance of water and electrolyte balance are
the basic interventions to treat EVD due to the lack of
specific anti-EBOV drugs. Every ETC designed their
treatments protocol according to the protocols for viral
haemorrhagic fever under the urgent interim guidance
for case management established by the WHO and en-
dorsed by the Ministry of Health, which were similar.
Statistical analyses
Statistical analyses were performed with the aid of
SPSS, Version 17.0. (SPSS Inc., Chicago, IL, USA). The
overall survival rate was compared using Log-Rank
Test. Univariate and multivariate analyses were carried
out using the logistic regression model. The inter-
group comparisons were performed using Chi Square
Test. Receiver Operating Characteristic (ROC) curve
was plotted using the log10 value of blood EBOV viral
load and the survival rate. All the statistical tests were




A total of 773 suspected EVD patients were admitted to
Jui government hospital, among which 285 were con-
firmed with EVD. All patients with confirmed EVD re-
ceived supportive treatment and were followed up to the
endpoint (recovery or death). Among the confirmed
EVD patients, 152 were transferred to other treatment
centres and 133 treated in our centre. Of the total con-
firmed, 139 were female and 146 were male, 146 recov-
ered and 139 died, with an overall survival rate of
51.23 % (females 54.68 %, males 47.95 %). No significant
difference was found between the survival rates of fe-
males and males (P = 0.2558).
The average age of the EVD patients was 29.20 ±
16.37 years, and the median age was 28 years, interquar-
tile range were 19 years and 38 years (IQR, 19–38). The
youngest patient was 1 month old, and the oldest
80 years old. The ages were separated by the following
groups: 62 patients (21.75 %) were under the age of 16,
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144 patients (50.53 %) between 16 and 35, 60 patients
(21.05 %) between 36 and 60, and 19 patients (6.67 %)
above the age of 60. The median age was 29 (IQR, 17–
40) for the non-survivors and 27 (IQR, 17–35) for the
survivors.
The mean hospitalization time for survivors was 20.38 ±
7.58 days, and the median was 19 (IQR, 15–24) days. The
surviving patients were discharged after they had been
asymptomatic for 48 h, and they had been tested negative
for blood EBOV using RT-PCR assay. The mean
hospitalization time for non-survivors was 5.56 ± 6.11 days,
and the median was 4 (IQR, 3–6) days.
Survivors timeline to negative blood EBOV diagnosis
result
We investigated how long it took for the blood EBOV to
turn negative in the surviving patients. All 146 survivors
were followed up from the time of diagnosis (when
blood EBOV was first detected) to the time of recovery.
The median time for a surviving EVD patient to become
blood EBOV negative was 20.31 ± 7.62 days, and the
range was from 7 days to 49 days. Of the total number
of survivors observed, 63.69 % (93 cases) turned negative
for blood EBOV within 3 weeks after the diagnosis, and
87.67 % (128 cases) turned negative 4 weeks after the
diagnosis (Fig. 1).
Non-survivors hospitalization time
Among the 285 EVD patients who received treatment,
139 died (the fatality rate 48.77 %). Of the 139 non-
surviving patients, 60.43 % died within 4 days after ad-
mission, 79.86 % died during the first week, and more
than 90.00 % died within 2 weeks (Fig. 1).
Age stratified survival rate
To investigate the survival rate of EVD patients in differ-
ent age groups, the 285 EVD patients were divided into
three groups (age 0–6, age 7–59, and ≥60 years). The re-
sults showed that the survival rate for group 0–6 was
statistically lower than that of group 7–59 (P = 0.0424)
or group ≥60 (P = 0.0447) (Fig. 2). But the survival rates
for group 7–59 and group ≥60 were not statistically dif-
ferent (P = 0.6621, Kaplan–Meier Estimate) (Fig. 2). In
addition, we categorized the patients using the median
age (28 years) or 40 years as the cutoffs, and applied the
same statistical analysis, but no statistically significant
difference was found in the survival rates between
groups.
The viral load and the fatality rate of patients with EVD
We also looked into whether high viral load in the blood
was an indicator for high fatality rate. A Receiver Oper-
ating Characteristic (ROC) curve was plotted using the
blood viral values and the survival outcomes of the EVD
patients. Among the 285 patients, 27 died within 24 h of
admission. Such patients were tested positive using only
oral swab samples, and were excluded from this analysis.
A total of 258 patients with detectable blood EBOV virus
were included in the ROC curve analysis. The numbers
of EBOV copies were converted to log10 values for fur-
ther analysis. The results showed that the viral loads had
a high predictive power of patients’ outcome (P < 0.001).
The Areas Under Operator Curve (AUOC) were 0.663
(95 % CI: 0.593–0.733). From the ROC curve, when the
log10 viral value was greater than 5, the probability of
patients’ survival was less than 40 %; and when it was
greater than 6, the probability of patients’ survival was
less than 15 %. These results suggested that the viral
loads can be used as a potential prognostic biomarker
for EVD patients (Fig. 3a).
We selected 106 copies/ml as the cutoff value to div-
ide the patients into two groups (EBOV ≥ 106copies/
ml and < 106 copies/ml), and applied statistical analysis
Fig. 1 The time lapsed before survivors turned negative for blood
EBOV, and the time lapsed before non-survivors died. All patients
were confirmed with EVD in Sierra Leone
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(Fig. 3b). Kaplan–Meier Estimate showed that when
the blood EBOV titer was greater than 106 copies/ml,
the fatality rate was 60.37 % -remarkably higher than
that of the group with less than 10 6 copies/ml viral
load (39.02 %) (P = 0.0066).
Comparison of survivors and non-survivors about clinical
presentations
We analysed the clinical presentations of the EVD pa-
tients at the time of admission, of which 20 of the 285
patients were excluded due to incomplete data, making
the total number of patients studied and included in the
analysis to 265. Common findings of the clinical mani-
festations included fever (91.70 % of the patients),
weakness (91.32 %), loss of appetite (87.92 %), cough
(66.42 %), headache (66.04 %), joint pain (60.38 %), ab-
dominal pain (56.60 %), vomiting (53.21 %), diarrhoea
(53.21 %), muscle pain (48.30 %), chest pain (43.02 %), sore
throat (33.96 %), jaundice (33.58 %), conjunctivitis
(28.68 %), hiccups (21.51 %), bleeding (12.30 %), pain be-
hind eyes (11.32 %), confusion (8.30 %), and skin rash
(4.53 %). A number of variables between survivors and
non survivors were shown to be significantly different
amongst the EVD positive patients with known outcomes
including vomiting (P < 0.001), abdominal pain (P = 0.020),
jaundice (P < 0.001), conjunctivitis (P = 0.004), and confu-
sion (P < 0.001) (Fig. 4).
Multivariate analysis of factors associated with patients’
survival
To further explore which factors were associated with
the survival of EVD patients, a number of factors, in-
cluding a variety of symptoms (absent OR present), age
(years), gender (male OR female), viral load (log10 cop-
ies/ml), and treatment outcomes (survival OR death)
were included in the univariate and multivariate analyses
(Table 1). The univariate analysis showed that vomiting,
abdominal pain, jaundice, conjunctivitis, confusion, and
the viral load (P < 0.15) were good candidates for the
final Logistic Regression Model. The multivariate ana-
lyses showed that higher viral load, severe confusion,
vomiting, abdominal pain, and conjunctivitis indicated
poor prognosis in EVD patients (Table 1).
Discussions
Jui government hospital in Freetown, Sierra Leone was
approved as an EHC on Oct1, 2014 to receive suspected
EVD patients. Once the EVD cases were confirmed, the
patients were transferred to other ETCs such as P.T.S. 1,
Fig. 3 a Viral load as a predicator for the outcomes, Receive Operating Characteristic (ROC) curve. b Comparison of the survival rates of EVD
Patients with different viral loads. (≥106 group compared to <106 group:P = 0.0066)
Fig. 2 Comparison of the survival rates of EVD Patients in different
age groups. (0–6 group compared to 7–59 group, P = 0.0424; 0–6
group compared to 60+ group, P = 0.0447; 7–59 group compared to
60+ group, P = 0.6621)
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Kenema, 34 Military Hospital, Kerry Town and Goderich
Hospital in Freetown. Altogether 152 confirmed patients
were transferred to the above-mentioned ETCs. On Jan 1,
2015, Jui Government Hospital was approved as an ETC,
and patients began to receive treatment in this institution
thereafter. In the retrospective analysis, for the viral and
clinical characteristics of the EVD patients, we used data
from all patients with confirmed EVD at Jui Government
Hospital from October 1, 2014 to March 21, 2015. The
data included patients’ clinical presentations, time points
when blood EBOV turned negative, durations of hospital
stay, survival rates in different age groups, and other com-
parisons between survivors and non-survivors.
In the previous published reports, no detailed data was
available on how soon the blood EBOV turned negative
in EVD patients. Our observation revealed that blood
Fig. 4 Comparison of symptoms between survivors and non-survivors
Table 1 The association of the outcomes with the symptoms and the viral load in EVD patients
Variable Univariate P Multivariate Variable Univariate P Multivariate
P-value OR (95 % CI) P-value OR (95.0 % CI)
Gender 0.368 Age 0.641
Fever 0.223 Diarrhea 0.249
Weakness 0.201 Cough 0.524
Chest pain 0.469 Headache 0.300
Difficult swallowing 0.478 Sore throat 0.481
Pain behind eyes 0.210 Muscle pain 0.619
Skin rash 0.520 Hiccups 0.237
Loss of appetite 0.165 Joint pain 0.177
Confusion *0.000 *0.010 4.150 (1.401–12.293) Jaundice *0.032 0.198 1,513 (0.806–2.843)
Abdominal pain *0.000 *0.003 2.597 (1.387–4.865) Vomiting *0.000 *0.004 2,400 (1.319–4.368)
Viral load *0.000 *0.005 1.406 (1.108–1.784) Conjunctivitis *0.004 *0.035 2.058 (1.052–4.024)
Logistic regression model was used for the univariate analysis. *P < 0.05
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EBOV turned negative very slowly—only 63.69 % pa-
tients turned blood EBOV negative in 3 weeks. This par-
tially explained why EVD spread so widely and persisted
for so long in West Africa. The surviving EVD patients
in our study were discharged after the symptoms
remained absent for 48 h, and the blood samples were
negative for EBOV in two consecutive tests with quanti-
tative RT-PCR assay. The mean hospitalization time for
surviving patients was 20.38 ± 7.58 days. In other studies,
the researchers continued to monitor EBOV RNA levels
in sputum, saliva, conjunctiva swabs, stool, urine, and
sweat using real-time RT-PCR assay after the blood
EBOV RNA turned negative. They found that urine sam-
ples remained positive for EBOV RNA for as long as
13 days after blood turned negative,and sweat samples
remained positive throughout the observation period for
an additional 10 days (23 days after blood became EBOV
RNA negative [7]). Another study reported that EBOV
existed in cerebral spinal fluids and semen for much lon-
ger in EVD patients [8]. Even Varkey and colleagues de-
scribed a patient who recovered from EVD and
subsequently showed severe unilateral uveitis during
convalescence. In this case, viable Zaire Ebola virus was
detected in aqueous humour 14 weeks after the onset of
EVD and 9 weeks after the clearance of EBOV from the
blood [9]. Such findings warrant further investigations in
the future. Although it was unclear whether or not such
residual viruses were pathogenic, these findings sug-
gested that when EVD patients are recovered and dis-
charged, they should be put on continued quarantine for
a period of time to avoid close contact with other
people.
The Case Fatality Rates (CFR) of EVD was reported to
be between 40 % and 74 % [10–17]. In our study, the
total mortality rate was 48.77 % for confirmed cases,
which was similar to that in the previous reports. As a
trend observed in this outbreak, the fatality rate was
more than 70 % during the early stage, and dropped to
40 %–60 % at a later stage. This may be attributable to
the public’s poor awareness of this disease, the delay in
seeking treatment, the inadequate measures for diagno-
sis and treatment, and the limited media coverage when
the outbreak erupted. Later, as more awareness came
from the international medical associations causing
more international medical teams to arrive, the public
became better educated and the patients started to re-
ceive more effective diagnosis and treatment. Thus at
the later stage of the virus outbreak, early discovery,
early diagnosis, and early treatment helped bring the fa-
tality rate down.
We also made observations about the length of the
hospital stay for the non-survivors. We found that most
non-survivors died within 4 days after admission, which
was consistent with other reports [10–17]. Only 10 %
died after day 12 upon admission. This indicated that
EVD has high degree of virulence. It also suggested that
early diagnosis and early treatment is critical to the pa-
tients’ survival. Just as some scholars stated, the lack of
public awareness of the disease as well as the lack of
synergy among governments and international organiza-
tions contributed to the current epidemic [18]. The pub-
lic should be educated and instructed to seek medical
attention as early as they notice any symptoms, and the
proactive treatment should be deployed as soon as the
patients are admitted.
The age factor has been noted in the past EVD out-
breaks and remains an important factor in the current
outbreak [19–21]. The previous reports showed that older
age was associated with worse outcomes, and the associ-
ation between the two was often attributable to increased
coexisting conditions in the elderly [10, 11, 14, 15]. In con-
trast, we did not find statistically significant differences be-
tween the age of non-survivors and survivors in our study
(median age: 29 (IQR: 17–40) vs.27 (IQR: 17–35); average
age: 29.32 ± 16.34 vs.28.97 ± 16.52). In order to determine
the association between age and prognosis, we grouped
the patients using different cutoffs, including median age
(28), the cutoffs used in other studies (age 30, 40, 50), and
multiple age groups at intervals of 5 years. In our compari-
son of the different age groups, no association was found
between age group and prognosis. One distinction in our
study was that the mortality rate for younger patients
under the age of 6 was higher than the other age groups.
This may be explained as follows: in the beginning of the
EVD outbreak, adult patients encountered many compli-
cations such as diarrhoea-related electrolyte disorders and
secondary infections, but soon received sufficient fluid
therapy in many ETCs, so the mortality rate dropped
among those patients. But for young children, since there
was a shortage of paediatricians in many centres, the
paediatric patients may not always have received sufficient
attention or optimized therapy [22]. The young children
were unable to care for themselves and their daily fluid in-
take was not always guaranteed while solely depending on
the limited hospital resources. Additionally, poor access to
IV vessels in paediatric patients may limit both the
amount and the flow rate of fluid administered.
We also found that patients who presented the highest
viral loads had the worst outcome, as had been the case
for other strains of Ebola virus [10, 11, 16, 23]. Although
the diagnostic value was excellent for postmortem swab
samples [24], it was unclear how a Cycle Threshold (Ct)
value from an oral swab correlates with that from a
whole blood sample, therefore the viral load data for the
oral swab samples (27/285) were not included in the
analysis. The relationship between the viral load (copies
of EBOV per milliliter) and the fatality rate was investi-
gated. ROC curve analysis was plotted and a positive
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correlation was found between the two. A low viral load
was associated with a better survival outcome, whereas a
high viral load was an important indicator for fatality
rate. Our finding was consistent with those of the previ-
ous reports [10, 11, 16, 23]. Based on this finding, it is
plausible to assign patients with virus load of ≥106 cop-
ies/ml to dedicated wards, where they can receive en-
hanced medical support and palliative care if resources
allow, given their increased risk of death. It is note-
worthy that the 27 cases for which EVD was confirmed
using oral swab samples were all severely ill patients
who died soon after admission. Exclusion of these cases
may have introduced some bias in our results.
EVD was formerly named Ebola haemorrhagic fever,
and bleeding is one of its hallmarks. Bleeding was noted
among patients in previous outbreaks. However, in this
outbreak, the reported bleeding rates ranged from
2.27 % [11] to 51.00 % [10]. In our study, only 35 of 285
patients (12.28 %) suffered from visible bleeding during
their hospitalization, which is a relatively low number
when comparing to other reports [25]. This suggested
that bleeding may not be a major characteristic of EVD
patients in this outbreak. Such discrepancy may be asso-
ciated with the evolvement of the virus’s pathogenicity
as its genes undergo mutations.
Finally, we analysed which factors were associated with
patients’ outcomes. The incidences of various symptoms
in EVD patients reported here are consistent with those
of previous reports, with only minor differences. The
most common EVD manifestations on admission were
fever, weakness, loss of appetite, vomiting, cough, ab-
dominal pain, headache, joint pain, and diarrhoea. In
addition to factors such as age and viral load, previous
studies described many other important factors associ-
ated with fatal outcomes, including hiccups, haemor-
rhagic signs, fever, weakness, dizziness, diarrhoea,
myalgia, difficulty breathing, extreme fatigue, vomiting,
mental symptoms, loss of appetite, confusion, and con-
junctivitis [11–14, 16, 26]. The multivariate analyses in
each study may include one or more of the aforemen-
tioned presentations. This indicated that: first, none of
the clinical manifestations observed among patients in
this outbreak was unique; and second, the way the pa-
tient history information was collected may vary in each
study.
In our study, the multivariate analyses showed that
EBOV viral load, abdominal pain, confusion, conjunc-
tivitis, and vomiting were independently associated
with the death outcome of EVD patients. It is under-
standable that high viral load is related to fatality rate,
and that digestive discomfort may be associated with
patients’ prognosis. In our study, the most powerful
predictor of mortality in the multivariable regression
model was confusion at admission (P value = 0.010),
with an Odds Ratio of 4.150 (95 % CI: 1.401–12.293)
favouring mortality. This finding indicated that the
more severe the condition was at the time of admis-
sion, the higher the risk of death. We observed that
due the lack of peculiar presentations of EVD and the
less-developed health care capacity in Africa, many
patients failed to seek medical attention promptly after
they experienced some non-specific symptoms such as
fever, thus delaying the diagnosis and treatment. Some
patients died on their way to the hospital, some died
upon arrival before the physicians had the opportunity
to examine them, and yet some died on day 1 (11/285)
or day 2 (23/285) after admission. In these circum-
stances, it was too late for the patients to receive
proper treatment for such a severe disease. Therefore,
we should raise the public’s awareness that early dis-
covery, early diagnosis, and early treatment are
essential.
Early proactive intervention can significantly improve
the prognosis of the patients. In our clinical observa-
tions, we found that the clinical presentations in this
EVD outbreak was primarily severe gastro enteric symp-
toms, such as nausea and lack of appetite accompanied
by excessive vomiting and severe diarrhoea. Although
due to the limitations of the medical equipment, we
were unable to carry out laboratory tests to determine
the cause of death for each non-survivor, we suspected
that the loss of body fluids, abnormal metabolism, elec-
trolytes imbalance, and hypovolemic shock, which were
all secondary to the severe digestive tract disorder, may
have been the immediate causes in the death of most
non-surviving patients. The patients are usually ex-
tremely weak after the onset of the disease and cannot
eat or drink by themselves; therefore it is essential for
the medical staff, while taking precautions to protect
themselves, to administer adequate fluids to the patients
as early and as quickly as possible. Early initiation of
proactive fluid therapy, particularly in the first days of
hospitalization and even before the EBOV test results
are received, is vital to saving patients’ lives and reducing
fatality rate.
A few limitations exist in our study. First was the limi-
tation of the data. There were many challenges regarding
the collection of accurate clinical and epidemiological
data on site in West Africa. Heavy workload, language
barriers, and lack of an information technology infra-
structure which would otherwise allow healthcare pro-
fessionals to record data electronically at the point of
patient contact, had all contributed to the incomplete
data presented in our study.
The second limitation was that no analysis was avail-
able for the time period between symptom onset and ad-
mission, and in most cases it was difficult to pinpoint
the exact date when symptom started. The majority of
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the patients were not able to recall or describe when the
symptoms started; it was especially so for the more se-
vere patients.
Another drawback is the limitations on the clinical ob-
servations. As we described previously, some patients
were transferred to other ETCs before Jui Government
Hospital became a designated ETC, and the treatment
protocols in the other ETCs may not always be consist-
ent with the EVD SOP.
GI losses and electrolyte disturbances may be the
major causes of death in many EVD patients. Labora-
tory tests that provide comprehensive data on patients’
haematological and biochemical indicators can help de-
lineate the cause of death. More importantly, it may
also provide instructions for treatment, thus reducing
fatality rate. Unfortunately, we did not have a cross-
contamination-proof testing facility in place while our
centre was serving as an EHC or in its early stage of
serving as an ETC. Therefore, we were unable to deter-
mine whether the 139 non-survivors died of EVD com-
plications, related co-infections, or some other causes.
We only evaluated the severity of the illness by the
clinical manifestations, and transfused more fluid for
the patients with profound GI losses and those unable
to take oral fluids or medications. The biochemical
testing and the testing for co-infection with malaria
were not launched until a later stage due to the limita-
tion of laboratory facilities. Even then, such data was
only collected from a limited number of patients. While
the data was of some help to the treatment, it was not
sufficient for a meta-analysis.
In addition, we were not able to analyse the associ-
ation between the treatment protocols and the out-
come. During the 6 months of treatment, three
different health care teams rotated and the physicians
were on 6–8 h shifts. The medical staff professionals
had different ways of practicing, thus the medical his-
tory, symptoms and signs were recorded in different
manners.
Conclusions
In conclusion, for the patients confirmed with EVD, the
survival rate was 51.23 %. Some surviving patients did
not become blood EBOV negative until 4 weeks after ad-
mission or later. Most non-surviving patients died
within 1 week after admission. Patients under the age of
6 years and those with high viral load had a higher fatal-
ity rate. Patients who presented confusion, vomiting,
abdominal pain, and conjunctivitis at the time of admis-
sion were at higher risk of death. Such patients should
be the priority of medical attention and should be put
under intensive treatment, particularly during the first
week of hospitalization.
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